Aapro M S, Alberts D S
Invest New Drugs. 1984;2(3):329-30. doi: 10.1007/BF00175386.
Mitoxantrone (1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.
米托蒽醌（1,4 - 二羟基 - 5,8 - 双[2 - [(2 - 羟乙基)氨基]乙基]氨基）- 9,10 - 蒽二酮二盐酸盐，NSC 301,739）是一种新型氨基蒽醌衍生物，在治疗晚期乳腺癌（1,2）、淋巴瘤（3）和急性白血病（4）方面具有临床活性。我们对晚期头颈癌患者进行了一项米托蒽醌的II期试验，采用每三周一次的给药方案。
